Recruiting

Ertugliflozin

Sponsor:

Amsterdam UMC, location VUmc

Code:

NCT06983054

Conditions

Type 2 Diabetes

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ertugliflozine

low salt diet

placebo

high salt diet

Study Details

Brief summary:

SGLT2 inhibitors have demonstrated to mitigate cardiorenal risk in people with type 2 diabetes and are likely to play an increasingly large role in the treatment of patients with diabetes, chronic kidney disease and hypertension. Yet the underlying mechanisms of its protective effects are incompletely understood and the salutary effect may be altered by dietary factors such as sodium intake. Therefore, carefully designed mechanistic trials are needed to better understand the interplay between ertugliflozin and salt intake and to potentially modify salt intake to maximize treatment response. In addition, the study could contribute to hypotheses concerning the effects of SGLT2 inhibitors in combination with other drugs that affect sodium homeostasis and could help to explain the differences in kidney outcomes observed in (outcome) trials, which include different ethnicities with potential differences in dietary habits.

Conditions

Type 2 Diabetes

Study ID

NCT06983054

Start date

Jul 25, 2023

Status verified date

May, 2025

Completion date

Dec, 2025

Anticipated

Primary completion date

Dec, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Adults with previously diagnosed T2DM according to American Diabetes Association (ADA) criteria

  • HbA1c 6.5-10%
  • Age 18 - 85 years of age
  • Overweight or obese with BMI: >25 kg/m2
  • We will make every effort to enrol participants of all races/ethnicities."
  • Both sexes (females must be post-menopausal; no menses >1 year; in case of doubt, Follicle-Stimulating Hormone (FSH) will be determined with cut-off defined as >31 U/L)
  • Ability to provide signed and dated, written informed consent prior to any study procedures
  • Estimated GFR 60-90 ml/min/1.73m2 by CKD-EPI matching the eGFR range of most participants in VERTIS-CV
  • Sodium intake at baseline < 200 mmol/day
  • UACR < 30 mg/mmol
  • All participants need to be on a stable dose of diabetes medication, including Metformin, SU, DPP4-inhibitors, or insulin.
  • Participants suffering from hypertension need to be on a stable dose of RAS inhibitors. In case RAS inhibition is not tolerated, the participant should to be on a stable dose of other antihypertensive treatment.

Exclusion Criteria:

  • History of unstable or rapidly progressing renal disease NL80772.029.22 / DC2022ERTU DESIGN Protocol DESIGN, Study NO. 2022.0737 Version 5.0dd22-02-2024 14 of 45

  • Estimated GFR <60 mL/min/1.73m2 or eGFR > 90 mL/min/1.73m2 determined by CKD-EPI
  • UACR > 30 mg/mmol
  • Current/chronic use of the following medication: SGLT2 inhibitors, TZD, GLP-1RA, glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics Participants should be on a stable dose of antipsychotics, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Subjects on diuretics will only be excluded when these drugs cannot be stopped for the duration of the study.
  • Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) will not be allowed, unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e.

sports injury, headache or back ache). However, no such drug can be taken within a timeframe of 2 weeks prior to renal testing

  • History of diabetic ketoacidosis (DKA) requiring medical intervention (e.g. emergency room visit and/or hospitalization) within 1 month prior to the Screening visit.
  • Current urinary tract infection and active nephritis
  • Recent (<6 months) history of cardiovascular disease, including:

  • Acute coronary syndrome
  • Chronic heart failure (New York Heart Association grade II-IV)
  • Stroke or transient ischemic neurologic disorder
  • Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN
  • Active malignancy. History of malignancy is allowed unless the participant still has active treatment other than hormonal therapy.• History of or actual severe mental disease
  • Substance abuse (alcohol: defined as >4 units/day)
  • Allergy to any of the agents used in the study
  • Individuals who are investigator site personnel, directly affiliated with the study, or are immediate (spouse, parent, child, or sibling, whether biological or legally adopted) family of investigator site personnel directly affiliated with the study
  • Inability to understand the study protocol or give informed consent

Study Design

Enrollment

34 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Low salt diet with SGLT2i

10 days of SGLT2i treatment during 20 days of low salt diet

placebo comparator: Low salt diet with placebo

10 days of placebo during 20 days of low salt diet

active comparator: High salt diet with SGLT2i

10 days of SGTL2i during 20 days of high salt diet.

placebo comparator: High salt diet with placebo

10 days of placebo during 20 days of high salt diet.

Interventions

ertugliflozine

SGLT2i versus placebo

low salt diet

comparing low salt versus high salt diet

placebo

placebo tablet

high salt diet

high salt diet

Primary outcome measure

  • Blood pressure [ Time Frame: 7 months ]

Central Contacts and Locations

Locations

Childrens hospital colorado

Recruiting

Denver, Colorado, United States, 80045

Contacts

Jessica Kendrick, Prof.

303-724-4837Jessica.Kendrick@cuanschutz.edu

More Information

Sponsor

Amsterdam UMC, location VUmc

Last update posted

May 21, 2025

Last verified

May, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Amsterdam UMC, location VUmc on 2025-05-21.